Skip Ribbon Commands
Skip to main content
Navigate Up
Search
Test Code
Search
Laboratory Section
Test Category
Browse By Test Name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood (JAKXB)
Test Code: JAKXBSO
Synonyms/Keywords
​JAK2 Exon 12
JAK2 Exon 13
JAK2 Exon 14
JAK2 Exon 15
Janus Kinase 2 Gene
Janus Kinase 2 Gene Sequencing
Tyrosine Kinase Gene Sequencing
Tyrosine Kinase Mutuation
Test Components
JAKXB / JAK2 Exon 12 and Other Non-V617F Mutation Detection
Useful For
​Aiding in the distinction between a reactive cytosis and a myeloproliferative neoplasm, particularly when a diagnosis of polycythemia is being entertained; for use with blood specimens
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​No ​Whole Blood ​EDTA Lavendar Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​4.0 mL ​1.0 mL
Collection Processing Instructions
Invert several times to mix blood.  Send specimen in original tube.
Specimen Stability Information
Specimen Type Temperature Time
​Whole Blood ​ ​Refrigerate (preferred) ​5 days
​Ambient ​5 days
Rejection Criteria
Gross Hemolysis, Clotted Samples
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday through Friday ​10 days Mutation Detection in cDNA Using Sanger Sequencing
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.).
Reference Lab
Test Information

​This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Reference Range Information
Interpretive Report
Interpretation
The results will be reported as 1 of 2 states:
1. Negative for JAK2 mutation
2. Positive for JAK2 mutation
 Cautions :
A positive result is not specific for a particular diagnosis and clinico-pathologic correlation is necessary in all cases. A negative result does not exclude the presence of a myeloproliferative or other neoplasm.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
0027U

​1

Classification
​This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Synonyms/Keywords
​JAK2 Exon 12
JAK2 Exon 13
JAK2 Exon 14
JAK2 Exon 15
Janus Kinase 2 Gene
Janus Kinase 2 Gene Sequencing
Tyrosine Kinase Gene Sequencing
Tyrosine Kinase Mutuation
Test Components
JAKXB / JAK2 Exon 12 and Other Non-V617F Mutation Detection
Ordering Applications
Ordering Application Description
​Centricity

JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood (JAKXB)

​Cerner ​ 

JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood (JAKXB)

​COM ​ 

JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood (JAKXB)

If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​No ​Whole Blood ​EDTA Lavendar Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​4.0 mL ​1.0 mL
Collection Processing Instructions
Invert several times to mix blood.  Send specimen in original tube.
Specimen Stability Information
Specimen Type Temperature Time
​Whole Blood ​ ​Refrigerate (preferred) ​5 days
​Ambient ​5 days
Rejection Criteria
Gross Hemolysis, Clotted Samples
Useful For
​Aiding in the distinction between a reactive cytosis and a myeloproliferative neoplasm, particularly when a diagnosis of polycythemia is being entertained; for use with blood specimens
Test Information

​This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Reference Range Information
Interpretive Report
Interpretation
The results will be reported as 1 of 2 states:
1. Negative for JAK2 mutation
2. Positive for JAK2 mutation
 Cautions :
A positive result is not specific for a particular diagnosis and clinico-pathologic correlation is necessary in all cases. A negative result does not exclude the presence of a myeloproliferative or other neoplasm.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday through Friday ​10 days Mutation Detection in cDNA Using Sanger Sequencing
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.).
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
0027U

​1

Classification
​This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
For most current information refer to the Marshfield Laboratory online reference manual.